The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale

The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale

Aim. To evaluate the antifibrotic effect of bicyclol with promising clinical effects on diffuse parenchymal liver diseases.Materials and methods: We have included 40 adult male Wistar rats (weight, 180 to 200g) with experimentally inducted toxic F3 stage liver fibrosis. Control group consisted of 16...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. V. Zhdanov, A. V. Saulevich, K. V. Kozlov, S. M. Zakharenko, V. S. Sukachev, V. E. Karev, Yu. F. Zakharkiv, I. V. Potekhin, R. M. Mukhtarov, K. V. Kasianenko, S. S. Karyakin, M. G. Chernenok
Format:	Article
Language:	Russian
Published:	Journal Infectology 2021-01-01
Series:	Журнал инфектологии
Subjects:	fibrosis induction antifibrotic bicyclol experiment liver biopsy
Online Access:	https://journal.niidi.ru/jofin/article/view/1149
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The dynamic of psycho-emotional condition in patients with chronic HCV infection (F1-F3) treated with bicyclol
by: K. V. Kozlov, et al.
Published: (2025-03-01)

Comprehensive treatment of patients with type 2 diabetes, complicated by diabetic kidney disease, with concomitant non-alcoholic steatohepatitis
by: Z.Ya. Kotsiubiichuk, et al.
Published: (2025-04-01)

A clinical case of idiopathic pulmonary fibrosis against the background of comorbid pathology
by: A. V. Teteneva, et al.
Published: (2021-10-01)

Drug-induced liver injury in cancer patients
by: V. T. Ivashkin, et al.
Published: (2020-10-01)

Sarcoidosis: Key disease aspects and update on management
by: Robina K. Coker, et al.
Published: (2025-05-01)

Non-invasive diagnosis of fibrosis in patients with CHC and obesity
by: K. V. Zhdanov, et al.
Published: (2020-03-01)

Exploring the Antifibrotic Mechanisms of Ghrelin: Modulating TGF-β Signalling in Organ Fibrosis
by: Mei Li, et al.
Published: (2025-01-01)

Impact of Pirfenidone on Patient-Reported Outcomes in Patients With Idiopathic Pulmonary Fibrosis From the Pulmonary Fibrosis Foundation Patient RegistryTake-home Points
by: Mohleen Kang, MD, MS, et al.
Published: (2024-12-01)

Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review
by: Ignacio Español Montero, et al.
Published: (2025-06-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

Physalis angulata Linn. As a Potential Liver Antifibrotic Agent In Rats.
by: Muhammad Begawan Bestari, et al.
Published: (2024-01-01)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
by: Sebastian Majewski, et al.
Published: (2025-06-01)

Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study
by: Camilla S. Graham, et al.
Published: (2025-05-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Apigenin as a multifaceted antifibrotic agent: Therapeutic potential across organ systems
by: Xiaoyong Hu, et al.
Published: (2025-06-01)

Elimination of hcv-infection: a history with continuation
by: K. V. Zhdanov, et al.
Published: (2018-12-01)

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
by: Stefano Kette, et al.
Published: (2025-03-01)

Soluble human macrophage factors are able to inhibit TGF-β-induced differentiation of lung fibroblasts
by: A. A. Maksimova, et al.
Published: (2024-07-01)

Breaking new ground in pulmonary fibrosis: Targeting Pathways and Therapeutic Innovations
by: Swadip Mishra
Published: (2025-04-01)

Evolution of antiviral treatment chronic for hepatitis B, C and D
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database
by: Yasuhiro Kondoh, et al.
Published: (2025-05-01)

TGF-β inhibitors: the future for prevention and treatment of liver fibrosis?
by: Weili Wang, et al.
Published: (2025-06-01)

Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
by: L. P. Ananieva, et al.
Published: (2021-01-01)

Evaluation of the effectiveness and safety of interferon alpha-2b ointment and gel for prevention of acute respiratory infections in organized groups
by: K. V. Kozlov, et al.
Published: (2024-04-01)

The patient journey and burden of disease in progressive pulmonary fibrosis in Japan: a cross-sectional survey
by: Yuko Kaneko, et al.
Published: (2025-04-01)

A rational approach to the treatment of hepatic encephalopathy in patients with liver cirrhosis
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Connective Tissue Disease Associated Interstitial Lung Disease
by: Ju Hyun Oh, et al.
Published: (2025-04-01)

Electron microscopic changes in the nasal membrane of patients with COVID-19 depending on the clinical form and the period of the disease
by: E. V. Kryukov, et al.
Published: (2021-07-01)

Airway complications after lung transplantation: Perioperative risk factors and clinical outcomes
by: Siddhartha G. Kapnadak, MD, et al.
Published: (2025-08-01)

Tetrandrine slows disease progression on high-resolution computed tomography and lung function decline in artificial stone-associated silicosis: a retrospective cohort study
by: Shaowei Zhou, et al.
Published: (2025-07-01)

Role of clinical and postmortem morphological investigations in practice of infectionist
by: V. A. Zinserling, et al.
Published: (2014-09-01)

Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung DiseaseTake-Home Points
by: Angela Kaczorowski-Worthley, BSN, et al.
Published: (2025-06-01)

s MadCAM-1 as an immunological marker in the «gut liver axis» at patients with chronic hepatitis C and excess body weight
by: K. V. Zhdanov, et al.
Published: (2019-05-01)

Rosmarinus Officinalis L. essential oil: in Silico molecular docking and in vivo nematocidal activity on intestinal and muscular trichinellosis
by: Sara A. Abdel Salam, et al.
Published: (2025-07-01)

Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives
by: Konstantin V. Kozlov, et al.
Published: (2024-12-01)

Retrospective analysis of prostate cancer detection using mpMR/US-fusion and cognitive biopsy
by: V. S. Petov, et al.
Published: (2023-01-01)

The crystal structure of bicyclol, C19H18O9
by: Wang Fengfeng, et al.
Published: (2025-06-01)

Rationale for endomyocardial biopsy in the diagnosis of heart disease in children and adults
by: L. B. Mitrofanova, et al.
Published: (2021-12-01)

Pathomorphology of liver fibrosis in trepanobioptates of patients with steatohepatitis: main types, sources of development, features of progression
by: V. A. Tumanskiy, et al.
Published: (2017-12-01)

Interstitial lung diseases: a view on the problem
by: O. G. Sych, et al.
Published: (2025-06-01)